Compare SOAR & DRMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SOAR | DRMA |
|---|---|---|
| Founded | 2021 | 2014 |
| Country | United States | United States |
| Employees | N/A | 9 |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.3M | 4.9M |
| IPO Year | N/A | N/A |
| Metric | SOAR | DRMA |
|---|---|---|
| Price | $0.23 | $1.24 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | ★ 6.2M | 89.4K |
| Earning Date | 05-14-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $650.00 |
| P/E Ratio | $0.28 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.19 | $0.59 |
| 52 Week High | $4.36 | $7.33 |
| Indicator | SOAR | DRMA |
|---|---|---|
| Relative Strength Index (RSI) | 40.89 | 44.86 |
| Support Level | $0.20 | $1.13 |
| Resistance Level | $0.35 | $1.40 |
| Average True Range (ATR) | 0.04 | 0.09 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 24.29 | 23.64 |
Volato Group Inc operates an aircraft ownership program, provides ad-hoc charter flights, sells deposit products, and manages aircraft for owners in the private aviation industry. It offers fractional ownership, aircraft management, jet cards, deposit, and charter programs. The company's fractional programs provides flexible hours and a revenue share for owners in a fleet of HondaJets, optimized for missions of up to four passengers.
Dermata Therapeutics Inc develops and commercializes dermatology products for the treatment of common skin conditions. It focuses on leveraging prior clinical and technical expertise to develop OTC treatments for conditions such as acne, psoriasis, rosacea, and seborrheic dermatitis. The company is currently developing a once-weekly acne treatment system that utilizes an active ingredient from the OTC monograph in combination with the company's Spongilla technology. It intends to apply its Spongilla technology platform across a range of dermatologic and aesthetic skin applications, including intradermal delivery of botulinum toxin. The company's operates in one segment, which is the business of developing, branding, marketing, and commercializing direct to consumer skincare products.